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View Article Online
View Journal  | View IssueGeneral discussionDOI: 10.1039/C3FD90043F
Professor Alexander opened the discussion of the paper by Zhanglin Lin: Are
there changes in motility of the bacteria following changes in gene expression?
Professor Lin answered: This is something we did not look into. A very inter-
esting question.
Professor van Hest enquired: Is it possible to control the type of aggregates
formed in the bacteria, for example could vesicular structures be formed?
Professor Lin responded: This is a very intriguing question. We have only
concerned with ourselves with aggregates purely of proteins/peptides. To have
vesicular structures, one would have to involve other biopolymers such as lipids.
Dr Saiani commented: Using bacteria to produce protein, how reliable is the
protein sequence obtained? Is the cost of the approach used strongly aﬀected by
the length of the peptide tag used?
Professor Lin noted: The sequence is very reliable and the cost is generally not
aﬀected by the length.
Professor Hamley asked: Why do you need such a specic peptide sequence in
order to drive self-assembly? There has been work by others using amyloid
peptides for example to drive the aggregation of large globular proteins (you cite
some of this work in your paper) – these give non-specic assembly, perhaps your
sequences are more specic?
Professor Lin replied: The amyloid peptide that has been reported to perform
such a function is Ab42, a peptide with 42 amino acid residues. Our work is
signicant in two ways:
(1) Scientically, we found there are a number of short peptides (beyond the
amyloid peptide) that can cause proteins to form aggregates in vivo, in particular
the amphiphatic peptides that are commonly found in proteins. This might be
relevant to protein aggregation-related diseases.
(2) Technically, the short peptides found in our work are much safer to use in
applications such as in peptide tags for protein expression and purication. Also,
it is much more economical as these peptide tags account for a much smaller
percentage in fusion with a target protein.This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 331
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View Article OnlineDr Saiani remarked: Do the ion pair modications change the conformation
adopted by the peptides?
Professor Lin responded: Theoretically themodications should slightly change
the 18A peptide structure, but then it should remain in a helical conformation.
Dr Saiani asked: Is the eﬃciency of the protein recovery process aﬀected by the
conformation adopted by the peptide tag e.g. b-sheet or otherwise.
Professor Lin answered: Indeed, it seems at this point that the b-sheet
conformation works better.
Dr Kros asked: If Lys is changed to Glu, do you lose the snorkel eﬀect?
Professor Lin replied: Indeed yes. This is exactly what we set out to prove, and
we saw reduced association of the fusion protein with the cell membrane.
Dr Saiani enquired: Can you use the bacterial approach to synthesise other
species, such as polymers?
Professor Lin answered: Except for a limited number of cases such as poly-
(3-hydroxybutyrate), generally bacterial cells cannot do that.
Dr Saiani asked: How long are the bacteria kept alive for? What is the corre-
lation between length of experiment and amount of protein produced?
Professor Lin answered: Bacteria normally are kept alive for 1–2 days, but oen
the protein production reaches the peak within one day.
Dr Gouveia commented: Howmuch easier it is to solubilize proteins using this
system compared to those produced in usual inclusion bodies?
Professor Lin responded: There is no need to solubilize. The proteins in the
aggregates are in the native state. If we cleave oﬀ the attached self-assembling
peptides (say via the self-cleaving activity of an intein inserted in between), the
proteins are released in the soluble fraction.
Dr Gouveia noted: The folding of a recombinant peptide or protein produced
by bacterial systems aer its dissociation from inclusion bodies seldom corre-
sponds to the native one, which usually impairs its function. Does the use of these
self-assembling peptides allow recombinant proteins with native-like conforma-
tions to be retrieved?
Professor Lin replied: It is somewhat the opposite: these self-assembling
peptides allow the recombinant proteins to fold properly upon translation, and by
the self-assembling action of the peptides, the properly-folded proteins are driven
into active aggregates which retain the native state. At least, it seems this way
given the uorescent activity of GFP, and the activity results from other model
enzymes.332 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineProfessor van Hest asked: How does your system compare to the yeast
expression system with an excretion signal?
Professor Lin responded: It is quite diﬀerent. We have protein aggregates
formed inside E. coli, which is not amenable for secretion. Generally, the
expression level for E. coli is much higher than that for yeast, whether aggregates
are formed or not.
Dr Gouveia asked: Could these peptides be applied to other protein/peptide
production systems (e.g. yeast, insect, or mammalian cells)?
Professor Lin replied: In theory, they could. We have not tried this yet.
Dr Saiani asked: How much protein gets trapped in the aggregates aer
cleavage and centrifugation?
Professor Lin responded: It varies. For lipase A (21 KD), about 32% gets trap-
ped, for amadoriase II (49 KD), about 38%, for beta xylosidase (61 KD), about 86%.
Dr Saiani wondered: Which approach or technique could you use to improve
the protein extraction from the aggregates?
Professor Lin answered: It appears that the protein size matters – the larger the
target protein is, the more it gets trapped. Therefore, one way to improve the
eﬃciency of release is to make the aggregates loose upon recovery via
centrifugation.
Professor Hamley remarked: Why did you use the L6KD sequence? Is there
something specic about it?
Professor Lin replied: We have screened quite a number of peptides for the
ability to drive proteins into active aggregates in E. coli. L6KD is one of the
peptides that we found to perform such a function. At this point, we do not have a
specic rule as to which peptide may work.
Dr Saiani commented: What are the conditions, pH and salt content, in the
bacteria?
Professor Lin replied: As far as E. coli is concerned, the intracellular pH is
around neutral. The salt content is a more complex issue, but the concentration is
in the submolar range.
Dr Bittner opened the discussion of the paper by Saul Tendler:† Do you have
additional proof that your structures are tubes and not solid bres? AFM alone
may not suﬃce (see Bittner et al., Adv. Mater., 2008, 20, 2332–2336).† Prof. Tendler’s paper was presented by Dr Korolkov, The University of Nottingham, Nottingham, UK.
This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 333
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View Article OnlineDr Korolkov answered: Our study of the rst stages of dipeptide assembly have
indicated a tubular structure. Whether it remains so during the whole assembly is
under investigation.
Dr Saiani asked: What are the globular structures present on the tubes in the
pictures?
Dr Korolkov replied: These are structural elements whose structure needs to be
assessed with other techniques, perhaps UHV STM or TEM. Ambient AFM on its
own cannot resolve their inner arrangement.
Dr Adams enquired: Do you know for denite that the diphenylalanine is
molecularly dissolved in the HFIP?
Dr Korolkov answered: Di-PhePhe solution in HFIP at given concentrations
appeared as a clear transparent liquid with no evidence of colloidal systems. It did
not scatter light when a laser was passed through it nor did it show any precip-
itation over a long period of time. So, yes, we believe it to be a true solution as
there is no experimental evidence indicating otherwise.
Dr Adams asked: What time scales are involved when changing from one
structure to another?
Dr Korolkov responded: I believe you are referring to the transition of dendritic
structures into needle-like crystals upon the exposure to 100% ambient humidity.
The exact time scale is not known to us. But we understand that it happens very
rapidly, probably within seconds or even less. That is based on our observation of
the process with a conventional CMOS-camera built into the optical microscope.
Dr Adams remarked: Have you looked at the crystal structure aer exposure to
humidity? Does it agree with other published structures?
Dr Korolkov replied: No we have not. Morphologically, as seen by AFM or
optical microscopy, they appear to look very similar to di-PhePhe monohydrate
crystals as supplied by Sigma-Aldrich.
Dr Saiani remarked: What are the characteristics of the mica surface used?
Freshly cleaved mica is charged; do the surface characteristics aﬀect the structure
formed? Have you tried to change the surface characteristics?
Dr Korolkov answered: We used a freshly cleaved mica surface. We have not
modied it further. We have not established if surface charge has any impact on
the formation of structures.
Dr Saiani asked: Why do mica surfaces trigger the formation of these
structures?
Dr Korolkov replied: We believe two factors play an important role. Namely, the
atomic atness of mica and strong substance–substrate interactions.334 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineDr Nieuwlandwondered: Is there a way to stabilise the structures and use them
in an application?
Dr Korolkov replied: We believe that this could be done via electron induced
polymerisation, although the possible electron induced damage may aﬀect the
ne structural arrangement.
Professor Hamley asked: Is there a monolayer of dipeptide coating the whole
mica, meaning the dendritic structure is unaﬀected by the mica substrate?
Dr Korolkov replied: It is a monolayer of dipeptide particles assembled in a
random fashion. They do cover areas of mica in between the dendritic struc-
tures, although such a monolayer is absent in close proximity (100–200nm
away) to the dendritic structures. Our understanding is that such particles
further assemble into tubular-like structures which further interact with each
other. We did observe such tubular assembly directly on mica surface without
the formation of randomly assembled particles monolayer rst. We argue that
mica provides an atomically at and strongly binding support for tubes’
assembly.
Dr Saiani enquired: How can the amount of water present be evaluated? What
is the role and eﬀect of water?
Dr Korolkov responded: We have not evaluated quantitatively the eﬀect of
water on the dendritic structure formation, although, as we have observed, water
does transform them into needle-like crystals. The eﬀect needs further
investigation.
Dr Saiani commented: We need tools to evaluate the role of water in the self-
assembly of peptides.
Dr Singh noted: Triuoroacetic acid is a common contamination source in
commercial peptides.
Dr Korolkov answered: We have not observed that contaminant when the
sample was analysed using high resolution MS.
Dr Squires asked: Can you take a small amount of diphenylalanine from your
dendrictic structure and use this as a seed to grow crystals, to determine whether
the packing of diphenylalanine molecules within the dendritic structure is the
same as that in previously observed crystals?
Dr Korolkov responded: We have not performed such experiments. But I
believe it should be possible to initiate crystal growth in such a way.
Professor van Hest opened the discussion of the paper by Mustafa Guler: Do
you see ra or domain formation? Is eﬃcient uptake an indication of domain
formation?This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 335
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View Article OnlineProfessor Guler answered: How the peptides are localized on the liposome is
not well-known. The enhanced uptake of the liposomes upon peptide integration
is an indirect sign of peptide integration.
Dr Singh asked: Have you done any temperature dependent studies on the
delivery of anticancer drugs?
Professor Guler replied: We have not tested our formulations at varying
temperatures.
Professor Lecommandoux enquired: Can you quantify or at least estimate how
much peptide you need at the surface of the liposomes to have good uptake?
Professor Guler responded: Over the range of peptide concentrations we have
used in this study, an increased amount of peptide can enhance the cargo uptake
results.
Professor Cui commented: Is there any particular reason for you to use the C12
(lauric acid) and not C16 (palmitic acid) hydrocarbon as the tail in your molecular
design? Also, is the purpose of using proline in your PA to disrupt its assembly
into nanobers?
Professor Guler answered: Lauric acid was used as a hydrophobic segment to
integrate peptide into the liposomal system. Other lipids should work as well.
Dr Kros asked: What is total lipid concentration used in this study? How does
this system compare to cationic liposomes?
Professor Guler replied: We do not know.
Dr King commented: Do you know the mechanism by which your system can
transfer cargo across a cell membrane?
Professor Guler answered: We have not tested the uptake mechanism. It is
possible that it is through electrostatic interactions between the cellular
membrane and the peptides.
Dr Garanger asked: How does the amphiphilic peptide alone (without lipo-
somes) self-assemble? How do the self-assemblies formed from the peptide alone
(used as the control in your biological experiments) compare to peptide-func-
tionalized liposomes in terms of size?
Professor Guler responded: The peptide alone was not used as a carrier system.
Liposomes and peptides were mixed during the liposome formation. We have not
studied structures formed by peptides.
Mrs Kessler asked: What is the loading capacity of the hydrophobic and
hydrophilic compound in comparison to the amount you need for a therapy?336 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineProfessor Guler noted: It is in the range of typical liposomal systems.
Dr Paternostre commented: Did you measured the solubility of your amphi-
philic peptide and its critical aggregation concentration? Upon dilution there is
risk that the peptide is extracted from the lipid bilayer of the liposome through a
dynamic equilibrium process.
Professor Guler responded: We have not.
Professor Hamley asked: Can you please comment on the mode of interaction
of your cell penetrating peptide amphiphile with the lipid membranes? Can you
eliminate the possibility of peptide amphiphile molecules interacting at the
surface of the liposomes rather than embedding within the membrane?
Professor Guler said: Unfortunately, we do not have direct evidence to support
organization of peptides within the lipid membrane. We expect that the lipid
segment could be localized in the liposomal membrane and that the arginine
residues are interacting with the surface of the membrane.
Professor Alexander noted: There was a notable step up at higher concentra-
tion. Why?
Professor Guler replied: We do not know.
Dr Nieuwland commented: In the introduction of the paper youmention that a
non-covalent approach is preferred over a covalent approach because more
activity is retained. How does the activity of your systems compare to systems with
covalent linkage (for example chemical ligation?).
Professor Guler answered: We have compared our peptide functionalization
results against bare liposomes. We have not studied a covalent functionalization.
Dr Kros asked: At the highest concentration used, are you sure liposomes are
still being formed? Is this proven by, for example, TEM?
Professor Guler replied: We imaged the liposome samples with TEM. No
change in size was observed.
Professor Lin opened the discussion of the paper by Honggang Cui: Will the
nanoparticle structures be disrupted in the stomach environment (pH around 2)?
Professor Cui answered: These drug nanoparticles are expected to be admin-
istered though intravenous injection. I have done some testing at low pH to check
their stability and found the nanotubes could be stable at low pH for several
hours. But eventually, all these nanoparticles are designed to break down,
releasing the free CPT.
Professor Lin asked: How would you use the nanotubes for drug delivery?This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 337
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View Article OnlineProfessor Cui replied: There are two issues we need to address before we
evaluate these CPT nanotubes in an animal setting. The rst issue is the control of
the nanotube length and length polydispersity. Then, we need to study how to
change the surface chemistry without losing the nanotube morphology. Aer
these, we will plan to test these nanotubes in appropriate models through an
intravenous injection pathway.
Dr Adams noted: The TEM images of folic acid show large objects. Doesn't the
CD data suﬀer from scattering issues?
Professor Cui responded: Yes. This is a good point. The CD spectra are aﬀected
by the presence of larger objects that scatter very strongly. The overall intensity of
absorption would likely be attenuated. However, given that the CD measures the
absorption diﬀerence of le and right handed circularly-polarized light, it is
unlikely the observed supramolecular chirality (intensity sign, peak position) is
induced by the large object scattering, although their intensity is more or less
aﬀected. We did not attempt to extract too much information from the CD
spectra.
Professor Kinbara commented: Both lamentous nanostructures and micron-
sized platelets are formed from the same compound in diﬀerent solvent
compositions. If the composition of the solvent is changed aer the formation of
these assemblies, do these structures revert to the other?
Professor Cui replied: The transition from lamentous nanostructures to
micron-sized platelets will take place with the addition of water into methanol,
however, this transition is not reversible. Once we obtain these single-crystal-like
platelets, they do not change to the nanober structures even when the solvent
composition was reversed back to containing a higher percentage of methanol. In
the presence of water, the platelets are very stable. One way to access the nano-
ber morphology from these platelets might be to lyophilize the solution and
then resolubize the resulting powder in pure methanol.
Professor Cavaco-Paulo asked: What happens when the self-assembled struc-
tures are put in water with a physiological buﬀer? What happens to the structures
in blood?
Professor Cui answered: Folic acid in PBS buﬀer assembles into nanobers,
similar to those formed in pure methanol. For the CPT drug amphiphiles, they
could form either nanobers or nanotubes depending on the treatments. We have
not studied the stability and morphological changes of the produced nano-
structures in blood, and expect to conduct these experiments soon.
Professor Lecommandoux commented: Using drugs as building blocks for self-
assembly is a nice concept. In this area, the group of Patrick Couvreur (Chatenay-
Malabry, France) especially demonstrated the benet of the concept of “squale-
nization” for the delivery of gemcitabine, the self-assembled nanoparticles thus
formed being able to be transported by a particular mechanism. In your case, and338 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlinein a more general perspective, to what extent you can anticipate the bioavailability
of the drug aer conjugation and self-assembly?
Professor Cui responded: Thanks for pointing out the work by Patrick Couv-
reur. The “squalenization” is an elegant demonstration of the concept of creating
drug assemblies with a high and controlled drug loading. This is indeed an
emerging and promising area that may have a great impact on cancer nano-
therapeutics, although there are still many experiments to be done to push this
conceptual work to the clinical stages.
Regarding the bioavailability, I cannot give you a straight answer because we
have not done any in vivo experiments to evaluate it. In pharmacology,
bioavailability is usually used to evaluate a formulation that is not given through
intravenous (i.v.) injection. By denition, the bioavailability of a drug given
through intravenous injection is considered to be 100%. Since both our drug
amphiphiles and the "squalenization" formulation are expected to be delivered
through i.v. injection, the bioavailability of the drug amphiphile should be 100%.
I think what you really refer to is the percentage of the “free drug” available to the
tumors. It will be very diﬃcult to evaluate this because not only do the supra-
molecular drugs need to be delivered to the target sites and dissociate into
monomeric units, but also the free drugs (CPT in this case) must be released
from the conjugated form. In our in vitro experiments, we have already found out
that the retarded release of CPT, as a result of forming supramolecular nano-
structures, has a great impact on the eﬃcacy of the drug amphiphiles in several
cancer cell lines.
Dr King enquired: Do you have any thoughts on how you might be able to
target the delivery of your system to specic places in the body, or to specic cell
types?
Professor Cui answered: This is exactly what we expect to do with our system
eventually. In addition to the passive targeting strategy of taking advantage of the
EPR eﬀects, we plan to incorporate cell-specic or organ-specic ligands into our
system for active targeting. This is not trivial and there are lots of experimental
parameters that need to be worked out.
Dr Squires asked: If you wanted to add functional groups to give your drug
assemblies specic targeting (eg RGD motif), where might you add these to your
structures?
Professor Cui replied: Synthetically speaking, this can be done rather readily. If
the specic targeting ligands are peptides, for example, the RGD motif to which
you referred, this incorporation process could be just part of the peptide
synthesis. If the targeting ligands are non-peptidic small molecules, this can be
done using lysine as a branching point.
Dr Squires enquired: Have you done X-ray diﬀraction to provide evidence for
the tetramer stacking shown in Fig. 4?This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 339
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View Article OnlineProfessor Cui responded: No, we have not done X-ray diﬀraction experiments
to provide direct evidence for the tetramer stacking among folic acids. Folic acid
is known to form a tetramerized disk through Hoogsteen hydrogen bonding, and
this has been studied by others using X-ray diﬀraction techniques. On the basis of
the previous reports, we assume this would be the case in our system.
Dr Squires asked: What is the evidence so far for the molecular arrangement
shown in the nanober structure?
Professor Cui replied: For the folic acid nanobers formed in methanol, we
measured the diameters of these nanobers as observed using TEM imaging and
found the measured value is in general agreement with the expected size of the
tetramerized folic acid disk. We therefore propose that the observed folic acid
bers are formed by stacking the folic acid disks in one dimension.
Professor Stupp commented: One would expect that targeting eﬃciency would
be aﬀected by the shape of the supramolecular assemblies. The shape is likely to
change with the nature of the drug. Could you comment on the strategies that
might be used for maintaining shape invariance over widely varying chemical
structures among drugs?
Professor Cui answered: You are right that the targeting eﬃciency of supra-
molecular assemblies will most likely be aﬀected in several ways if their shapes
are changed. This could be good or bad, depending on how it is altered, and also
on the purpose of the intended use. In the design of a self-assembling drug
amphiphile, it is almost certain their self-assembly behavior is heavily dependent
upon the chemical structure of the conjugated drug. The question here is to what
extent such a diﬀerence will be suﬃcient to lead to a change in shape or
morphology. We recently have found that for drug amphiphiles containing one
drug and one short peptide capable of forming intermolecular hydrogen bonding,
the resulting morphology is oen one dimensional and dominated by the peptide
segment. This observation is consistent with your work on the peptide amphi-
philes – the nanober morphology is very tolerant to the length of the alkyl tail.
However, if two or more drugs are conjugated, we found that the drug structures
have a huge impact on the shape of the assembly.
Professor Stupp asked: In addition to the loading issue, what are the other
critical features that self-assembling drugs would improve for therapies?
Professor Cui replied: Our recent studies show that the release rate of the drug
from the self-assembled nanostructures can be regulated by the packing order of
drug molecules within the assemblies in addition to the design of the linker
chemistry. Another benet is the protection of the hydrolysable or degradable
drugs from being accessed during circulation.
Professor Stupp enquired: Could the self-assembling drug platform be
improved through the use of cross-linking using hydrolysable bonds? This would
presumably help preserve the supramolecular shape, which is an important
feature for targeting.340 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineProfessor Cui responded: Yes, we are currently working on a few cross-
linking strategies to stabilize the drug assemblies. We are particularly inter-
ested in enzymatic degradable linkers such as MMPs. The cross-linking
chemistry, as well as the triggered release of the drug molecules by enzymatic
cleavage of the cross-linker, is not trivial and we are seeking several strategies
to resolve the stability issues. Stability is a major concern when using small
molecular building units to create nanocarriers for the delivery of drugs and
imaging agents. We always expect the resulting supramolecular assemblies are
stable during the circulation so that we could have good control over the
carrier’s pharmacokinetic properties. At the same, when the particles reach
the targeted site, we hope these nanocarriers can break down to eﬀectively
release its cargo because only monomeric, unassembled drug molecules are
actually functional and biologically relevant. The use of hydrolysable or
enzymatically degradable cross-linkers presents a potential solution to solve
this issue.
Dr Squires asked: As the carrier is the drug itself, how can you control the
loading? If you change the loading don’t you also change the self-assembly?
Professor Cui said: The drug loading is dened by the molecular design,
precisely the fraction of the drug within the drug amphiphile. For a given drug
amphiphile, regardless of the nanostructures it could potentially form, the drug
loading is always the same. It is highly likely that when you change the molecular
design, the self-assembly behaviors will change accordingly. I think that this is
truly the beauty of the drug amphiphile design. You have control not only over the
drug loading, but also on the assembled nanostructures. The nanostructure
characteristics (size, shape and surface chemistry) are a very important design
consideration for the development of nanomedicines targeted for cancer
chemotherapy.
Professor Guler enquired: Do peptide conjugated drugs behave similar to the
drugs themselves in terms eﬃcacy?
Professor Cui replied: In terms of the in vitro eﬃcacy, none of the self-
assembling Camptothecin (CPT) drug amphiphiles is better than the free
drug. In our paper published early this year in J. Am. Chem. Soc. (2013, 135(8),
2907–2910), we did a thorough study to evaluate CPT drug amphiphiles’ eﬃ-
cacy against a number of cancer cell lines. The free drug CPT is always the
most eﬀective one with the lowest IC 50 value. This is not surprising actually,
given that CPT itself can eﬀectively penetrate the cell membrane
through diﬀusion and is directly bioavailable. Our recent results suggest that
the retarded release of CPT from the self-assembled supramoelcular nano-
structures accounts for one of a few factors that contribute to the
reduced eﬃcacy. The true advantage of using nanocarrier-based systems is to
improve the drug’s targeting eﬃciency to tumors, which can only be
evaluated in animal models. We expect that these drug amphiphile
nanostructures will perform much better than the free drug in animal
experiments.This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 341
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View Article OnlineProfessor Guler commented: Peptide conjugated drugs should be tested in
terms of their eﬃcacy and side eﬀects. These cannot be compared to the initial
drug.
Dr Singh opened the discussion of the paper by Joerg Kressler: Why does the
branched polymer adsorb faster than the linear one? What is the role of
branching?
Professor Kressler replied: The hyperbranched Ch-PEG-hbPG adsorbs quickly
and strongly, the linear Ch-PEG-lPG more slowly. The reason for this diﬀerence is
thought to be the polymers’ architecture and the resulting spatial molecular
conformations in the aqueous environment. For Ch-PEG-hbPG, the cholesterol
unit is exposed and free for direct insertion into the phospholipid membrane and
the kinetics of the interaction depends mainly on the diﬀusion of the polymer
from the aqueous bulk phase. The coiled conformation of the linear copolymer,
PEG-lPG, shields the hydrophobic moiety, hindering the hydrophobic interaction
with the phospholipid membrane.
Professor van Hest asked: How generally applicable is the stabilisation of the
polymersome structure using BSA? Could you take any type of biotemplated
protein?
Professor Kressler said: As observed using CLSM, the protein coating (BSA-
Streptavidin) triggers the formation of polymersomes by allowing the adsorption
of an ordered polymer layer on its surface. However, our results indicate that the
protein layer does not have a stabilizing role once the polymersomes have been
formed.
Although we only tested the BSA-Streptavidin system, it is possible that other
protein coatings could also trigger the formation of polymersomes, but certainly
not just any protein would do it. For example, a specic interaction between the
PGM block of PGM-PPO-PGM and streptavidin was found previously using
molecular dynamic simulations (J. Kressler et al., ACS Macro Lett., 2012, 1, 1016–
1019).
Dr Kros enquired: Do the polymersomes detach from the surface?
Professor Kressler replied: Yes, they do. As shown in Figure 2a-A of the paper,
an overview of the surface aer polymersome formation shows some round spots
where only the BSA layer is le behind (blue spots) aer the polymersomes
detached from the surface.
Professor Alexander asked: What is the driving force behind crossing the
membrane?
Professor Kressler answered: The driving force for the membrane crossing
ability of the polymer is not fully understood. However it is known that some
amphiphilic polymers are able to diﬀuse across biological membranes, but
endocytosis is also a possibility. The actual mechanism will only be known aer
further experiments.342 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineDr Singh wondered: Does hydrogen bonding in the hyperbranched polymer
play any role for increased transfection?
Professor Kressler replied: We have not yet had any indications in that direc-
tion. Both hyperbranched Ch-PEG-hbPG and linear Ch-PEG-lPG are able to cross
the membrane and to form plenty of hydrogen bonds, therefore the diﬀerence
could be more related to the polymer conformation.
Dr Kros asked: Did you observe ip-opping, as the molecules are not very
hydrophilic?
Dr Squires added the question: Are the polymer molecules (and uorescent
probes) distributed symmetrically in both sides of the bilayer? Is there any
evidence for this?
Professor Kressler responded: Since we observed membrane-crossing of the
polymers, ip-opping is a possibility. However, we could not observe it because a
discrimination between the two leaets of the membranes is below the resolution
limit of the CLSM. Experiments allowing for such a discrimination, such as FRET
with GUVs lled with uorescent solutions, have not been performed yet. On the
other hand, the mechanism of membrane crossing could also be endocytosis.
Dr Kros asked: What happens if the salt concentration is increased?
Professor Kressler answered: All experiments with polymersomes and GUVs
were performed in pure water, thus the inuences of salts were not investigated at
all. For the cells experiments a standard DMEM cell culture medium was used.
Dr Squires enquired: In the cell penetration experiments, do the polymers
permeate as individual molecules or are they self-assembled? Do the uorescence
signals oﬀer any clues?
Professor Kressler replied: In the experiments with murine embryonic stem
cells the concentration of the Ch-PEG-hbPG polymer was 2 mM, which is below its
CMC. Therefore, it can be assumed that only single chains crossed the cell
membrane. We have not got any hints from the CLSM observations, such as self-
quenching phenomena, for self-assembly.
Dr Squires opened the discussion of the paper by Olga Vinogradova:‡ Where
you had a heterogeneous charge distribution, down to what range of length scales
for the spacing of negative and positive regions is your model applicable to?
Dr Lobaskin said: The problem has at least two important length scales: the
Debye length and the scale for the charge inhomogeneities. The characteristic
distance at which the heterogeneity can be detected is the longest spatial period of
the charge distribution. In the limit of small patches, the periodicity can be felt‡ Professor Vinogradova’s paper was presented by Dr Lobaskin, University College Dublin, Dublin,
Ireland.
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View Article Onlinedown to the molecular length scales. I can cite the interactions between poly-
electrolyte multilayer capsules, where the patterns are formed by individual
molecules, or experiments by Stellacci et al.,1 where the molecular size surface
stripes were shown to aﬀect the nanoparticle–membrane interaction as compared
to the homogeneously charged particles.
1 A. Verma, O. Uzun, Y. Hu, H.-S. Han, N. Watson, S. Chen, D. J. Irvine, and F. Stellacci,
Surface-structure-regulated cell-membrane penetration by monolayer-protected nano-
particles, Nature Materials, 2008, 7, 588–595.
Professor Mezzenga commented: Irregularity of charges on surfaces can lead
to a reduction in long-range repulsion, an eﬀect described by some authors as
patchy hydrophobic interactions. Can you account for this eﬀect in your approach
and how do you do this?
Dr Lobaskin replied: This was exactly the main point of this work. We aimed
to assess the contribution of the charge patches on the wall to the long-range
repulsion. We introduce the patchiness through the boundary conditions at
the surface and calculate the corrections to the disjoining pressure
coming from the average surface charge. In all cases, the patchiness reduces
the interaction as compared to the homogeneous case, which could indeed
provide an explanation for the phenomena you mention. In what regards to
the hydrophobic patches, the problem would be more challenging, as there is
currently no simple general model for hydrophobic interactions.
Professor Hamley asked: Using Fourier expansion, how can you account for
irregular charge patches?
Dr Lobaskin answered: The Fourier expansion of the surface charge distribu-
tion works equally well for arbitrarily-shaped patches or irregular patterns. The
diﬀerence with the case of regular charge stripes considered in this work is that
the expansion for irregular patterns would contain further terms with larger wave
vectors, which would reect all the important length scales of the charge distri-
bution. I should note, however, that the decay length for the potential away from
the surface and for the terms in the disjoining pressure depends on the wave-
length of the charge pattern. It is longer for the larger patches and shorter for the
smaller ones. Therefore, the biggest contribution to the pressure always
comes from the structures with the largest period or longer characteristic
wavelength.
Dr Squires wondered: Can active transport be incorporated into the model?
Dr Lobaskin replied: Yes. In our theory we calculate the induced potential on
the membrane due to the presence of the charged surface nearby. The corre-
sponding potential can be used to calculate the additional force acting on the
molecules travelling across the membrane.
Dr Squires enquired: What experimental data would you like to have available
to test your model?344 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineDr Lobaskin responded: Ideally, we would like to see the surface force
measurements (AFM or SFA) combined with the independent measurements of
the electrokinetic potential for the same surfaces. In this case, we would be able to
evaluate the main parameters and test the model in full.
Dr Squires asked: Is the experimental data on stability quantitative enough to
tell the diﬀerence between this model and a more basic model?
Dr Lobaskin replied: As the disjoining pressure between the membrane and
the charged surface behaves similar to the pressure between two charged
surfaces, it would be impossible to tell the case with a semipermeable wall from a
hard particle in a single experiment observing just the stability of the dispersion.
We can only extract some eﬀective surface charge on the membrane from the
measured interaction potential. However, if an independent experiment with
capsule electrophoresis is done, then the comparison of the zeta potential and
eﬀective surface potential can help us to evaluate the role of the membrane
permeability.
In regards to probing the charge distribution on the solid surface and the
presence of charge inhomogeneities, they can be detected by probing the
distances comparable to the typical period of the charge distribution. At these
separations, the force will deviate (decrease) from the exponential one that is
predicted for the homogeneous surface. The distance, at which the deviations will
start to appear, would indicate the largest length scale of the charge
inhomogeneity.
Mrs Kessler opened a general discussion of Professor Guler’s, Professor Cui’s,
Professor Kressler’s and Professor Vinogradova’s papers: There are two complete
diﬀerent approaches described in Professor Guler’s and Professor Cui’s papers to
encapsulate cancer drugs. What are the advantages of these two diﬀerent
approaches? If you think of potential applications, for which applications would
which approach be the best?
If you consider sensitive hydrophobic compounds like vitamins, does one of
these approaches lead to a protection of the encapsulated material from envi-
ronmental stress, like for example UV-light?
Professor Cui said: One advantage of using drugs to build their own nano-
structures is that the drug loading can be well controlled. Most carrier-based
systems possess a very low drug loading capacity (less than 5%), whereas in the
drug amphiphile system the drug loading is precisely dened by the molecular
design. In my opinion, the creation of drug nanostructures could potentially
improve, or partially solve the drug loading issue in a carrier-based system, but it
does not directly address the grand challenge in cancer chemotherapy – that of
specic targeting to the tumor sites. It should be clear that high drug loading is
not always desirable, particularly for drugs with very high potency. Nevertheless,
the drug amphiphile system at least provides one additional option allowing for
quantitative control of drug loading. Of course there are many experiments to be
done in order to translate this concept into a platform technology. Speaking of the
delivery of sensitive hydrophobic compound like vitamins, it is certain that
encapsulation of the vitamin into the hydrophobic cores of polymeric micelles,This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 345
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View Article Onlineliposomes, or peptide amphiphile nanobers would keep the drug away from
water. It is a feasible and sound approach to use nano-carriers for drug protection.
However, the most justiable reason to use a nanoscale architecture as carriers to
deliver anticancer drugs, in my opinion, is to modify the drug’s pharmacokinetics
proles to achieve better tumor targeting, not to protect the drug from degrada-
tion although most carriers do protect drugs from hydrolysis and enzymatic
degradation. For vitamins that are highly sensitive to water, you can simply
increase the dose to generate the desired therapeutic eﬀects. If vitamins do not go
to the targeted organs, cells, or receptors, they less likely to lead to severe prob-
lems to the patients. As for anticancer drugs, simply increasing the dose is not an
option due to the side eﬀects; specic targeting to the tumor is the strategy, and
the reason to use nanocarriers.
Professor Guler added: Our work aimed to contribute to liposomal drug
delivery studies. Several drug delivery systems can be used as a carrier.
Dr Squires wondered: What are the major scientic barriers at the moment to
drug delivery in general?
Dr Bittner responded: Thinking about the future, I could imagine very small
autonomous systems that actively move to the point of delivery and release their
drug cargo. This is no doubt that there are many unsolved problems on a rather
fundamental level (material, assembly, propulsion, fuel, immunogenicity, proper
size), but they might be solved.
Professor Guler added: Liposomes are normally used for the systemic delivery
of drugs. Sometimes, they might enhance solubility, stability and targeted
delivery of drugs.
Professor Stupp addressed Professor Guler: Liposomes have presumably not
been very successful due to poor stability in vivo. How does incorporation of
the cell-penetrating peptide amphiphile in the liposome aﬀects the
stability issue? Also, how is the peptide amphiphile incorporated in the
liposome; do you expect segregation of these molecules within the bilayer
membrane?
Professor Guler answered: The addition of peptide molecules decreases the
stability of the liposomes compared to the bare samples. The localization of the
peptides on the liposome could not have been detected in this work.
Professor van Hest commented: Two main issues regarding the general
acceptance of nanomedicine are reproducibility and scalability of nanocarrier
systems.
Professor Cui responded: Precisely said. When ling for investigational new
drug application for clinical trials in the United States, the FDA requires that the
applicant must have the manufacturing information included in the application.
This information is assessed to ensure that the company can adequately produce
and supply consistent batches of the drug.346 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineDr Bittner noted: An interesting alternative to bres are aggregates of proteins
with a well-dened mass. They can be found in virus-based nanostructures, e.g.
bacteriophages, plant viruses, or virus-like particles. Other examples are non-
virus cages, such as apoferritin.
Professor Stupp said: One of the great challenges in the eld is to understand
the mechanisms and pathway dependence of the self-assembly of complex
biomolecules such as peptides and their derivatives in order to achieve repro-
ducibility of the supramolecular structure. This is particularly important in
therapies for which the supramolecular construct is the therapy and not simply
the peptide or some other biomolecule.
Dr Squires commented: Could it be argued that it is not worth worrying about
targeting if the problem of reproducibility in self-assembling systems hasn’t been
resolved?
Dr Kros noted: Endosomal escape is another problem in drug delivery, which
needs to be addressed in order to develop eﬃcient delivery systems.
Dr Garanger stated: When developing a low molecular weight drug, one has
NMR to exactly assess the chemical structure of the active substance and all
impurities of the drug can be determined and quantied. It is muchmore diﬃcult
to characterize drug-loaded nanocarriers with the same level of precision, since
routine characterization techniques only give a global picture of the population
and not of each individual in that population. This is even more true when the
complexity of the systems increases (ligand-decorated nanocarriers, multiple
drug-loaded nanocarriers, etc.).
Professor Cui responded: This is exactly right. Accurate characterization of
drug-loaded nanocarriers or drug-polymer conjugates presents a big challenge to
the development of eﬀective nanomedicines due to the inherent polydispersity of
these systems.
Professor Stupp added: Yes I agree with this comment. However, what will
transform the eld of drug delivery will be our ability to target therapies to specic
tissues and organs through the bloodstream. This requires ligand-decorated
nanocarriers which are obviously more complex than simple drugs. The problem
is addressed to some extent through the use of molecules to construct the
nanocarriers which contain the drug as part of their covalent structure.
Professor Alexander commented: Knowledge of the self-assembly processes is
important in the pharmaceutical industry, but a detailed mechanistic under-
standing across multiple length scales is missing.
Professor Lin responded: We have been screening for peptides that can
promote the aggregation of proteins in vivo. Indeed, mechanistically, we still have
yet to come up with a general rule as to what peptides can perform such a
function, although we know that hydrophobicity and amphipathicity are impor-
tant. A better mechanistic understanding would allow a rational design of suchThis journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 331–348 | 347
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View Article Onlinepeptides, and a better understanding of protein aggregation and the associated
diseases in vivo.
Professor Cavaco-Paulo noted: The conditions of self-assembly are important.
We need to get closer to reality and think about availability to cells.
Miss Makwana commented: Although the eld of self-assembly has led to the
development of many sophisticated architectures, for drug delivery applications
there are a few developmental barriers which need to be addressed. In vivo issues
such as immune recognition towards self-assembling systems can prove to be a
limitation. For example consider opsonization, whereby the attachment of
proteins to the self-assembled system can lead to enhanced immune recognition
and clearance from within the body leading to decreased therapeutic eﬃcacy. For
this reason it is important that during development we routinely perform
experiments that take this into account.
Professor Stupp said: In the context of systemic drug delivery applications of
self-assembled systems, one must consider what aspects of the supramolecular
structure, for example shape, are critical for eﬀective targeting not only to tumors
but also generally to specic organs and parts of the vasculature. It is also
important to understand how supramolecular structures change once in the
bloodstream. Furthermore, diﬀerent aspects of supramolecular structure are
possibly important in localized tissue delivery.348 | Faraday Discuss., 2013, 166, 331–348 This journal is ª The Royal Society of Chemistry 2013
